Clinical Trials Logo

Clinical Trial Summary

This study is a cluster (clinic level) randomized pragmatic trial to compare the effectiveness of MA Health Coaching (MAC) delivered by non-clinician primary care staff (i.e., MAs) versus usual care (UC) in improving diabetes clinical control among individuals with poorly controlled type 2 diabetes mellitus (T2DM).


Clinical Trial Description

The study will be conducted in the primary care environments of two distinct, yet representative healthcare systems in San Diego County: Neighborhood Healthcare (a San Diego County FQHC system and designated Patient-Centered Medical Home, serving predominantly ethnic minority, low income patients) and Scripps (a large, non-profit, private insurance-based health system, serving predominantly Caucasian, middle-to-higher income patients). Six hundred patients at intervention (n=2; patient N=300) and control (n=2; patient N=300) clinics, aged 18 and older, with T2DM, and glycosylated hemoglobin (HbA1c) ≥ 8.0%, and/or low-density lipoprotein cholesterol (LDL-C) ≥ 100 mg/dL, and/or systolic blood pressure (SBP) ≥ 140 within the last 60 days, will be identified and enrolled using electronic health records (EHRs). Primary clinical outcomes of HbA1c, LDL-C, and SBP assessed as part of quarterly (or annual, for LDL-C), standard-of-care medical visits will be extracted from EHRs over 12 months. Changes in patient-reported behavioral (diabetes self-care) and psychosocial (quality of life, patient activation) outcomes will be evaluated via telephone assessment in a subset of intervention and control (N=300 total) participants at baseline, month 6, and month 12. A thorough process evaluation will be conducted to establish reach, acceptability/feasibility, adoption/maintenance, and fidelity of the intervention and will integrate patient, MA, and primary care provider perspectives. Cost-effectiveness will also be examined from the health system perspective. Principles of community engaged research were incorporated in intervention and study planning and will be sustained throughout the research period. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02643797
Study type Interventional
Source Scripps Whittier Diabetes Institute
Contact
Status Completed
Phase Phase 3
Start date March 7, 2016
Completion date April 19, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT05102149 - Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus Phase 3
Withdrawn NCT03423355 - Dapagliflozin Effect on Erythropoiesis and Physical Fitness Phase 4
Terminated NCT01923389 - Multiple Dose Study Of PF-05231023 In Obese Adult Subjects Phase 1
Completed NCT02218099 - A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease Phase 1/Phase 2
Completed NCT05607160 - A Study to Observe How Insulin Glargine 300 U/ml is Working and is Tolerated in Elderly Patients ≥75 Years of Age With Type 2 Diabetes
Completed NCT05628090 - A Study of an Existing Database to Assess the Treatment Persistence to Basal Insulin in Type 2 Diabetes Mellitus Patients in a Structured Patient Education Program in India
Completed NCT03656744 - A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM) Phase 2
Completed NCT01002807 - Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State Phase 1
Recruiting NCT04943861 - Human Immunodeficiency Virus (HIV) Food Insecurities N/A
Completed NCT02759107 - A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM) Phase 1
Completed NCT05294458 - A Randomised, Open-Label Study to Evaluate the Relative and Absolute Bioavailability of Cotadutide in Healthy Subjects Phase 1
Recruiting NCT06327815 - Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM Phase 4
Completed NCT02219646 - Diabetes & Vardenafil Phase 2
Recruiting NCT05761301 - A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM Phase 1/Phase 2
Completed NCT04504396 - Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy Phase 3
Completed NCT01991093 - Multiple Electrode Aggregometry & Clopidogrel Resistance
Completed NCT01871558 - Vildagliptin/Metformin in T2DM Patients Starting Basal Insulin Phase 3
Completed NCT01407003 - Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Assessment of LIK066 in Healthy Subjects and in Patients With Type 2 Diabetes Mellitus (T2DM) Phase 1/Phase 2
Completed NCT01127308 - A Radiolabeled Mass Balance Study of [14C]-Ertugliflozin (PF04971729, MK-8835) In Healthy Male Participants (MK-8835-038) Phase 1
Completed NCT00337610 - Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus Phase 3